Exogene
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies for solid tumours by combining deep learning and
Focus: Drug discovery platform
Team: Federio Paoletti (CEO) and Andrea Mambrini (CTO)
Website: https://exogene.co.uk/
See other Drug discovery organisations
-
Enedra is harnessing the power of synthetic lethality and advanced computational Systems Biology to create therapeutics. -
GlamorousAI is AI-first preclinical biotech focusing on the discovery of novel chemistry for challenging targets. -
Human Centric Drug Discovery helps patients with central nervous disorders by making it easier to develop drugs for their diseases. -
Kantify has developed ZeptoNet - a novel AI technology that can perform in silico high-throughput screening...
Be part of SBC Catalyser Programme!
Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.
Contact MarcoCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.